The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Immunologic profiling and clinical outcome in HER2+ breast cancer patients treated in a neoadjuvant phase II study: A step forward to understand trastuzumab activity.
R. Dolcetti
No relevant relationships to disclose
D. Crivellari
No relevant relationships to disclose
E. Muraro
No relevant relationships to disclose
D. Martorelli
No relevant relationships to disclose
G. Miolo
No relevant relationships to disclose
D. Lombardi
No relevant relationships to disclose
S. Massarut
No relevant relationships to disclose
T. Perin
No relevant relationships to disclose
R. Talamini
No relevant relationships to disclose
E. Turchet
No relevant relationships to disclose
E. Comaro
No relevant relationships to disclose
A. Carbone
No relevant relationships to disclose
A. Veronesi
No relevant relationships to disclose